Travatan Z (Travoprost Ophthalmic) - Summary

TRAVATAN Z SUMMARY

TRAVATAN Z®
(Travoprost ophthalmic solution) 0.004%

Travoprost is a synthetic prostaglandin F_2α analogue.

TRAVATAN Z® ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication.

See all Travatan Z indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Travatan Z (Travoprost Ophthalmic)

Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy. [2011.09]
PURPOSE: The purpose of this study is to compare the safety and intraocular pressure (IOP)-lowering efficacy of travoprost/timolol in a benzalkonium chloride (BAK)-free fixed combination preserved with polyquaternium-1 (TRA/TIM BAK-free), with travoprost/timolol-fixed combination preserved with BAK (TRA/TIM), in patients with open-angle glaucoma or ocular hypertension... CONCLUSION: Travoprost/timolol BAK-free demonstrated equivalence to travoprost/timolol preserved with BAK in efficacy. No clinically relevant differences in the safety profiles of travoprost/timolol BAK-free and travoprost/timolol preserved with BAK were identified.

The comparison of the effects of latanoprost, travoprost, and bimatoprost on central corneal thickness. [2011.08]
PURPOSE: To compare the effects of latanoprost, travoprost, and bimatoprost on central corneal thickness (CCT)... CONCLUSIONS: Topical therapy with prostaglandin analogues is associated with CCT reduction. Latanoprost, travoprost, and bimatoprost have a similar effect on CCT.

A 12-week, double-masked, parallel-group study of the safety and efficacy of travoprost 0.004% compared with pilocarpine 1% in Chinese patients with primary angle-closure and primary angle-closure glaucoma. [2011.08]
OBJECTIVE: To examine the intraocular pressure-lowering efficacy and safety of travoprost 0.004% and pilocarpine 1% in Chinese patients with primary angle-closure (PAC) and primary angle-closure glaucoma (PACG) after laser iridotomy in China... CONCLUSIONS: Travoprost 0.004% once daily provides effective IOP-lowering efficacy with significantly greater IOP reduction from baseline when compared with pilocarpine 1% 4 times daily at 4 PM over the 12-week period. Travoprost 0.004% once daily is safe and well tolerated in PAC or PACG patients.

Timolol versus brinzolamide added to travoprost in glaucoma or ocular hypertension. [2011.07]
BACKGROUND: To compare the efficacy and safety of timolol 0.5% versus brinzolamide 1.0% when added to travoprost monotherapy in patients with primary open-angle glaucoma or ocular hypertension... CONCLUSION: Both adjunctive combinations moderately reduced IOP in patients inadequately controlled with travoprost monotherapy, with timolol being slightly stronger 8 hours after instillation. Adjunctive treatment with brinzolamide and travoprost may be an alternative for patients not tolerant or not responsive to treatment with timolol and travoprost.

24-Hour intraocular pressure control between travoprost/timolol fixed combination, latanoprost/ timolol fixed combination and standard timolol in primary open angle glaucoma and ocular hypertension. [2011.03]
CONCLUSION: A fixed combination of Travoprost 0.004% and Timolol 0.5% is as effective as a fixed combination of Latanoprost 0.005% and Timolol 0.5% and are better than Timolol 0.5% in 24-hour IOP control.

more studies >>

Clinical Trials Related to Travatan Z (Travoprost Ophthalmic)

Three Month Safety and Efficacy Study of TRAVATAN� Versus Travoprost Ophthalmic Solution, 0.004% [Not yet recruiting]
A multi-center, observer-masked, randomized, parallel group efficacy and safety study of TRAVATAN® versus a new formulation of Travoprost Ophthalmic Solution, 0. 004%

Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN� Z) or Bimatoprost 0.01% [Recruiting]
Subjects are dosed once daily with either TRAVATAN®Z or LUMIGAN® at 8PM for 6 weeks and then are switched for a further 6 weeks to the other product either TRAVATAN®Z or LUMIGAN®. The primary efficacy variable: To demonstrate non-inferiority in the Intraocular Pressure (IOP) lowering efficacy of travoprost 0. 004% (TRAVATAN® Z) to that of bimatoprost 0. 01% after 6 weeks of treatment. Secondary efficacy variable: To detect a difference in IOP lowering efficacy of travoprost 0. 004% (TRAVATAN® Z) and bimatoprost 0. 01% measured at individual time points post dose after 6 weeks of treatment.

AR-12286 Fixed Dose Combination [Not yet recruiting]
This is a double-masked, randomized, controlled study assessing the safety and ocular hypotensive efficacy of two AR 12286/travoprost fixed-dose combination products compared to Travatan® Z in patients with elevated intraocular pressure

An Efficacy and Tolerability Study of TRAVATAN� Versus LUMIGAN� [Recruiting]

The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye [Recruiting]

more trials >>

Reports of Suspected Travatan Z (Travoprost Ophthalmic) Side Effects

Intraocular Pressure Increased (3),  Eyelid Oedema (2),  Bladder Prolapse (2),  Hypersensitivity (2),  Urinary Incontinence (2),  Visual Acuity Reduced (2),  Headache (2),  Pharyngeal Oedema (2),  Heart Rate Abnormal (2),  Nervousness (2), more >>